SEATTLE, Wash. (November 1, 2016)— Immusoft Corporation, a Seattle, Wash.-based gene therapy company, has closed on $2.74 million of a $3 million fundraising round. Founders Fund’s FF Science and Technium Partners led the investment. The round was oversubscribed and Immusoft says it expects to close on the remaining amount shortly.
Biotech seeking approval for clinical trial to treat MPS I